Literature DB >> 19506257

Inhibition of PCSK9: a powerful weapon for achieving ideal LDL cholesterol levels.

Daniel Steinberg1, Joseph L Witztum.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19506257      PMCID： PMC2701045          DOI： 10.1073/pnas.0904560106

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  14 in total

1.  Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.

Authors:  Jonathan C Cohen; Eric Boerwinkle; Thomas H Mosley; Helen H Hobbs
Journal:  N Engl J Med       Date:  2006-03-23       Impact factor: 91.245

Review 2.  A receptor-mediated pathway for cholesterol homeostasis.

Authors:  M S Brown; J L Goldstein
Journal:  Science       Date:  1986-04-04       Impact factor: 47.728

3.  Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9.

Authors:  Shirya Rashid; David E Curtis; Rita Garuti; Norma N Anderson; Yuriy Bashmakov; Y K Ho; Robert E Hammer; Young-Ah Moon; Jay D Horton
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-01       Impact factor: 11.205

4.  Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.

Authors:  Marianne Abifadel; Mathilde Varret; Jean-Pierre Rabès; Delphine Allard; Khadija Ouguerram; Martine Devillers; Corinne Cruaud; Suzanne Benjannet; Louise Wickham; Danièle Erlich; Aurélie Derré; Ludovic Villéger; Michel Farnier; Isabel Beucler; Eric Bruckert; Jean Chambaz; Bernard Chanu; Jean-Michel Lecerf; Gerald Luc; Philippe Moulin; Jean Weissenbach; Annick Prat; Michel Krempf; Claudine Junien; Nabil G Seidah; Catherine Boileau
Journal:  Nat Genet       Date:  2003-06       Impact factor: 38.330

5.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

Authors:  Paul M Ridker; Eleanor Danielson; Francisco A H Fonseca; Jacques Genest; Antonio M Gotto; John J P Kastelein; Wolfgang Koenig; Peter Libby; Alberto J Lorenzatti; Jean G MacFadyen; Børge G Nordestgaard; James Shepherd; James T Willerson; Robert J Glynn
Journal:  N Engl J Med       Date:  2008-11-09       Impact factor: 91.245

6.  A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates.

Authors:  Joyce C Y Chan; Derek E Piper; Qiong Cao; Dongming Liu; Chadwick King; Wei Wang; Jie Tang; Qiang Liu; Jared Higbee; Zhen Xia; Yongmei Di; Susan Shetterly; Ziva Arimura; Heather Salomonis; William G Romanow; Stephen T Thibault; Richard Zhang; Ping Cao; Xiao-Ping Yang; Timothy Yu; Mei Lu; Marc W Retter; Gayle Kwon; Kirk Henne; Oscar Pan; Mei-Mei Tsai; Bryna Fuchslocher; Evelyn Yang; Lei Zhou; Ki Jeong Lee; Mark Daris; Jackie Sheng; Yan Wang; Wenyan D Shen; Wen-Chen Yeh; Maurice Emery; Nigel P C Walker; Bei Shan; Margrit Schwarz; Simon M Jackson
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-14       Impact factor: 11.205

7.  PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide.

Authors:  LiXin Shan; Ling Pang; Rumin Zhang; Nicholas J Murgolo; Hong Lan; Joseph A Hedrick
Journal:  Biochem Biophys Res Commun       Date:  2008-07-31       Impact factor: 3.575

8.  Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype.

Authors:  Kara N Maxwell; Jan L Breslow
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-26       Impact factor: 11.205

9.  PCSK9: a convertase that coordinates LDL catabolism.

Authors:  Jay D Horton; Jonathan C Cohen; Helen H Hobbs
Journal:  J Lipid Res       Date:  2008-11-19       Impact factor: 5.922

10.  Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor.

Authors:  Christopher J Duff; Martin J Scott; Ian T Kirby; Sue E Hutchinson; Steve L Martin; Nigel M Hooper
Journal:  Biochem J       Date:  2009-05-01       Impact factor: 3.857
View more
  34 in total

1.  Dyslipidaemia: PCSK9 antibodies: a dividend of the genomics revolution.

Authors:  Michael H Davidson
Journal:  Nat Rev Cardiol       Date:  2013-09-10       Impact factor: 32.419

2.  Human genetics as a foundation for innovative drug development.

Authors:  Alexander Kamb; Sean Harper; Kari Stefansson
Journal:  Nat Biotechnol       Date:  2013-11       Impact factor: 54.908

3.  Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters.

Authors:  Bin Dong; Minhao Wu; Hai Li; Fredric B Kraemer; Khosrow Adeli; Nabil G Seidah; Sahng Wook Park; Jingwen Liu
Journal:  J Lipid Res       Date:  2010-01-04       Impact factor: 5.922

Review 4.  Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.

Authors:  Richard Kones
Journal:  Vasc Health Risk Manag       Date:  2013-10-21

5.  Fine-mapping of lipid regions in global populations discovers ethnic-specific signals and refines previously identified lipid loci.

Authors:  Niha Zubair; Mariaelisa Graff; Jose Luis Ambite; William S Bush; Gleb Kichaev; Yingchang Lu; Ani Manichaikul; Wayne H-H Sheu; Devin Absher; Themistocles L Assimes; Suzette J Bielinski; Erwin P Bottinger; Petra Buzkova; Lee-Ming Chuang; Ren-Hua Chung; Barbara Cochran; Logan Dumitrescu; Omri Gottesman; Jeffrey W Haessler; Christopher Haiman; Gerardo Heiss; Chao A Hsiung; Yi-Jen Hung; Chii-Min Hwu; Jyh-Ming J Juang; Loic Le Marchand; I-Te Lee; Wen-Jane Lee; Li-An Lin; Danyu Lin; Shih-Yi Lin; Rachel H Mackey; Lisa W Martin; Bogdan Pasaniuc; Ulrike Peters; Irene Predazzi; Thomas Quertermous; Alex P Reiner; Jennifer Robinson; Jerome I Rotter; Kelli K Ryckman; Pamela J Schreiner; Eli Stahl; Ran Tao; Michael Y Tsai; Lindsay L Waite; Tzung-Dau Wang; Steven Buyske; Yii-Der Ida Chen; Iona Cheng; Dana C Crawford; Ruth J F Loos; Stephen S Rich; Myriam Fornage; Kari E North; Charles Kooperberg; Cara L Carty
Journal:  Hum Mol Genet       Date:  2016-12-15       Impact factor: 6.150

Review 6.  PCSK9 inhibition: current concepts and lessons from human genetics.

Authors:  Fatima Rodriguez; Joshua W Knowles
Journal:  Curr Atheroscler Rep       Date:  2015-03       Impact factor: 5.113

7.  Evolution evolves: physiology returns to centre stage.

Authors:  Denis Noble; Eva Jablonka; Michael J Joyner; Gerd B Müller; Stig W Omholt
Journal:  J Physiol       Date:  2014-06-01       Impact factor: 5.182

8.  Targeted disruption of the idol gene alters cellular regulation of the low-density lipoprotein receptor by sterols and liver x receptor agonists.

Authors:  Elena Scotti; Cynthia Hong; Yuko Yoshinaga; Yiping Tu; Yan Hu; Noam Zelcer; Rima Boyadjian; Pieter J de Jong; Stephen G Young; Loren G Fong; Peter Tontonoz
Journal:  Mol Cell Biol       Date:  2011-02-22       Impact factor: 4.272

Review 9.  Evolocumab: Considerations for the Management of Hyperlipidemia.

Authors:  Barbara S Wiggins; Jeffrey Senfield; Helina Kassahun; Armando Lira; Ransi Somaratne
Journal:  Curr Atheroscler Rep       Date:  2018-03-06       Impact factor: 5.113

10.  Small Molecule Inhibitors of the PCSK9·LDLR Interaction.

Authors:  Jaru Taechalertpaisarn; Bosheng Zhao; Xiaowen Liang; Kevin Burgess
Journal:  J Am Chem Soc       Date:  2018-02-26       Impact factor: 15.419
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.